Insiders who reported open-market trades in the last 12 months at the companies James V. Caruso files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jarrod Longcor - $25K in CLRB purchases and sales in the last 12 months
John Neis - $732 in CLRB purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
James V. Caruso is a corporate insider, tracked as President & CEO, Director of Cellectar Biosciences, Inc. (CLRB). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did James V. Caruso last file a Form 4?
The most recent primary Form 4 on record is dated 9 July 2026, one of 3 filings going back to 2025.
Has James V. Caruso been buying or selling stock?
Recorded transactions: 4 open-market purchases ($75K) and 0 open-market sales across all tracked filings.
James V. Caruso is President & CEO, Director of Cellectar Biosciences, Inc. (CLRB). 3 SEC Form 4 filings on record going back to 2025, most recently on 9 July 2026. Most recent open-market trade: bought $25K of CLRB on 12 May 2026. Lifetime open-market purchases: $75K.
Recent transactions
2
The latest 2 SEC Form 4 transactions reported by James V. Caruso.
InsiderAlpha's records for James V. Caruso go back to 2025: 3 primary Form 4 filings, an average of 1.5 per year. The typical open-market purchase is $19K (4 buys totaling $75K). The largest single buy on record is $50K of CLRB in 2025. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
